Century Therapeutics(IPSC) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates – Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – – Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary ef icacy and tolerability data in heavily pretreated relapsed/refractory (R/R) CD1 ...